Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndromeKelly S. Chien, Guillermo Garcia‐Manero, Kimberly Sheppard et al.|British Journal of Haematology|2021Cited by 64
MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic SyndromesKunhwa Kim, Kelly S. Chien, Faustine Ong et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 1
Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromesKelly S. Chien, Guillermo Garcia-Manero, Ziyi Li et al.|Blood|2025Cited by 1
MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic SyndromesKelly S. Chien, Guillermo Garcia‐Manero, Kunhwa Kim et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 0
Poster: MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic SyndromesKelly S. Chien, Guillermo Garcia‐Manero, Kunhwa Kim et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 0